Plain Language Summaries is part of Taylor & Francis Group.

  • Taylor & Francis
  • About us
  • Our journals
  • Our Digital Hubs

Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK.

Taylor & Francis
logo
 
  • How to
  • FAQs
  • Publications
  • Advisory Panel
    • Plain Language Advisors
    • Scientific Content Advisors
  • Supporters
  • Blog
  • About us
  • Contact Us

enzalutamide

22nd Jan 2026

EORTC 1333/PEACE-3 research on enzalutamide with or without radium-223 for advanced prostate cancer patients with bone metastases: a plain language summary

13th May 2025

Real-world survival rates for advanced prostate cancer patients using abiraterone or enzalutamide treatments: a plain language summary

18th Oct 2024

Enzalutamide in metastatic hormone-sensitive prostate cancer: A summary of the ARCHES and ENZAMET follow-up studies

28th Aug 2024

The TALAPRO-3 study design: a plain language summary

This is a summary of a research article originally published in the Journal of Urology. The PROSPER study involved men who had a type of advanced prostate cancer called non-metastatic castration-resistant prostate cancer (nmCRPC). In patients with nmCRPC, their prostate cancer keeps growing even after traditional hormone treatments. In these patients, rising prostate-specific antigen (PSA) levels suggest that cancer is active but CT and bone scans show that it has not spread to other parts of the body. Everyone in this study received androgen deprivation therapy (ADT) either with the medicine enzalutamide or a placebo. Enzalutamide is a medicine that can slow or stop androgens, such as testosterone, from making prostate cancer grow. The main results of the PROSPER study showed that patients with nmCRPC treated with enzalutamide and ADT lived longer than patients treated with placebo and ADT. In this study, researchers wanted to know if the findings were different depending on how much patients’ PSA level declined after enzalutamide treatment. Researchers also wanted to know if this made a difference in how long patients lived without the cancer spreading to other parts of their body
10th Aug 2023

A plain language summary looking at whether declines in prostate-specific antigen level indicates how long patients with advanced prostate cancer will live when treated with enzalutamide

25th Nov 2022

Which traits affect how long patients with advanced prostate cancer live when treated with enzalutamide?

Copyright © 2026 · Plain Language Summaries · Terms and conditions · Privacy policy · Cookie policy